This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Hepatitis C, Chronic
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups. To determine and compare the safety and tolerability of P1101 + Ribavirin across treatment groups.

Provided treatments

  • Biological: PEGASYS 180 µg Q1W
  • Biological: P1101 180 µg Q1W, 48 doses
  • Biological: P1101 270µg Q1W, 48 doses
  • Biological: P1101 450µg Q2W, 24 doses

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01587586. The sponsor of the trial is PharmaEssentia and it is looking for 107 volunteers for the current phase.
Official trial title:
An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection